Health Care · Pharmaceutical Preparations

HRTX HERON THERAPEUTICS, INC. /DE/ SEC Filings & Insider Trading Activity 2026

company
CIK 818033157 filings
Russell 2000

HRTX at a glance

HERON THERAPEUTICS, INC. /DE/ (HRTX, SEC CIK 818033) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), HERON THERAPEUTICS, INC. /DE/ (HRTX) reported revenue of $154.9 million (up 7.4% from FY2024) and a net loss of $20.2 million. Diluted EPS was -$0.12.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding HERON THERAPEUTICS, INC. /DE/ (HRTX) shares worth $10.3 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$154.9M
+7.4% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$10.3M · +1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 3.03 · Item 7.01 · Item 1.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $35.3M, down $3.0M YoY, with acute care $15.1M vs $12.3M and oncology $20.1M vs $25.9M
  • Gross margin 74.6% vs 68.8% YoY, operating margin (4.7%) vs (10.7%)
  • Best segment acute care sales up 22.5% to $15.1M, worst oncology sales down 22.2% to $20.1M
  • Cash, cash equivalents and short-term investments $23.4M; operating cash use $4.5M versus $18.4M
  • Proposed Asset Sale expected first quarter 2027, with $145.0M cash and 14,583,333 CorMedix shares; covenant default risk remains without closing or funding

Risk Factors

  • Newly added asset-sale risk: CorMedix transaction announced November 8, 2026, requiring stockholder approval and other closing conditions
  • Most material update, liquidity: $23.4 million cash and possible covenant noncompliance could trigger debt acceleration and going-concern doubt
  • Regulatory risk: Post-sale assets may trigger Investment Company Act regulation, restricting investments, operations, and equity compensation
  • Legal risk: June 1, 2026 Azurity judgment invalidated two patents and found ten others not infringed, with appeal briefing completed November 4, 2026
  • Market risk: Nasdaq bid price below $1.00 triggered deficiency notice, with compliance required by December 22, 2026

AI summary of the HRTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 3.03: Material Modification to Rights of Security Holders

  • Amendment No. 2 to the Tax Benefit Preservation Plan modifies security-holder rights
  • The amendment’s specific terms appear under Item 1.01 and determine the practical shareholder impact

Item 7.01: Regulation FD Disclosure

  • Joint press release announces Purchase Agreement for Buyer’s acquisition of substantially all HRTX assets
  • Proposed transaction requires HRTX stockholder approval and regulatory clearances before closing

Item 1.01: Entry into a Material Definitive Agreement

  • Asset sale to CorMedix: $145.0M cash plus 14,583,333 CorMedix shares, transferring substantially all operating assets and liabilities
  • Additional contingent value: 5.0% royalties above $25.0M annual sales, plus ZYNRELEF earn-outs of $25.0M and $30.0M

Item EX-99.1: Item EX-99.1

  • CorMedix to acquire substantially all Heron assets for $145M cash plus 14,583,333 shares, approximately $222.6M upfront value
  • Portfolio adds four commercial products and approximately $150M trailing-twelve-month net product revenue
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Earnings Press Release furnished as Exhibit 99.1, containing the substantive financial details

Item EX-99.1: Item EX-99.1

  • Q3 2026 revenue $35.3M, down 7.8% YoY, as oncology declines outweighed Acute Care growth
  • ZYNRELEF revenue $10.6M, up 13.8%; APONVIE revenue $4.5M, up 49.3%
Filed Sep 29, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Exclusive U.S. commercialization rights for multiple products, with sublicensing and worldwide manufacturing rights
  • Regulatory and sales milestones, royalties, and expense reimbursements create future cash obligations tied to product performance

AI summaries of HRTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HRTX

Don't miss the next HRTX filing

  • Alerts as it files. A push when HRTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HRTX, by share count.
  • Ask anything. An AI agent that reads every HRTX filing and answers with sources.

HRTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hensley Mark EarlMNov 6, 2026-
Hensley Mark EarlFNov 6, 2026$0.29
Hensley Mark EarlMNov 6, 2026-
Forbes William PMOct 31, 2026-
Duarte IraMOct 31, 2026-
Forbes William PFOct 31, 2026$0.28
Duarte IraMOct 31, 2026-
Collard Craig AMOct 31, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$144.3M$154.9M
Gross Profit-$105.6M$113.6M
Operating Income--$11.5M-$2.5M
Net Income--$13.6M-$20.2M
Gross Margin-73.2%73.3%
Op. Margin--8.0%-1.6%
Net Margin--9.4%-13.0%
Balance Sheet
Total Assets-$233.1M$255.9M
Equity--$33.7M$14.3M
ROE-40.4%-140.9%
Per Share
EPS$-0.80$-0.09$-0.12
Cash Flow
Operating CF--$22.5M-$27.6M
CapEx$1.5M$1.7M$317K

Source: XBRL data in HERON THERAPEUTICS, INC. /DE/ (HRTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HRTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HRTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$10.3M
Q2 202624$15.0M
Q1 202625$32.7M
Q4 202522$57.0M
Q3 202523$57.3M
Q2 202524$88.4M
Q1 202524$58.0M
Q4 202418$30.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HRTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 10, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Oct 21, 2026--
4Oct 21, 2026--
4Oct 21, 2026--
8-KSep 29, 2026Analysis-
8-KAug 14, 2026Analysis-
8-KAug 10, 2026Analysis-
10-QAug 10, 2026Analysis
4Aug 10, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Jul 20, 2026--
4Jul 20, 2026--
4Jul 20, 2026--
8-KJun 25, 2026Analysis-
4Jun 17, 2026--

Related Health Care companies

All Health Care →

HRTX SEC filings: frequently asked questions

Which institutions hold HRTX stock?

As of September 30, 2026, the largest HERON THERAPEUTICS, INC. /DE/ (HRTX) holders among the 13F filers tracked by SignalX were BlackRock ($3.1 million), Vanguard Capital Management LLC ($2.5 million), State Street Corp ($1.0 million), AQR Capital Management ($624,000), Renaissance Technologies LLC ($492,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HRTX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), HERON THERAPEUTICS, INC. /DE/ (HRTX) reported revenue of $154.9 million (up 7.4% from FY2024) and a net loss of $20.2 million. Diluted EPS was -$0.12. The figures come from the XBRL data in the 10-K.

What did HRTX report in its latest 8-K?

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K on November 9, 2026 reporting Item 3.03 (Material Modification to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure) and Item 1.01 (Entry into a Material Definitive Agreement). Amendment No. 2 to the Tax Benefit Preservation Plan modifies security-holder rights.

What are the latest HRTX SEC filings?

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 10, 2026.

What is HRTX's SEC CIK number?

HERON THERAPEUTICS, INC. /DE/ (HRTX)'s SEC Central Index Key (CIK) is 818033. EDGAR lists every HRTX filing under that number.

Ask anything about HRTX

The research agent reads HRTX's filings, financials, insider trades and 13F holders, then answers with sources.